Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices

被引:55
作者
Barbour, April [2 ]
Scaglione, Francesco
Derendorf, Hartmut [1 ]
机构
[1] Univ Florida, Dept Pharmaceut, Coll Pharm, Gainesville, FL 32610 USA
[2] GlaxoSmithKline, King Of Prussia, PA USA
关键词
Anti-infectives; Tissue distribution; Pharmacokinetics/pharmacodynamics; EXPOSURE-RESPONSE ANALYSES; IN-VIVO PHARMACODYNAMICS; STAPHYLOCOCCUS-AUREUS; PROTEIN-BINDING; STREPTOCOCCUS-PNEUMONIAE; BACTERICIDAL ACTIVITY; HEALTHY-VOLUNTEERS; SOFT-TISSUES; CLINICAL PHARMACOKINETICS; AZITHROMYCIN CP-62,993;
D O I
10.1016/j.ijantimicag.2010.01.023
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
The pharmacokinetic/pharmacodynamic (PK/PD) indices useful for predicting antimicrobial clinical efficacy are well established. The most common indices include the time free drug concentration in plasma is above the minimum inhibitory concentration (MIC) (fT>(MIC)) expressed as a percent of the dosing interval, the ratio of maximum concentration to MIC (C-max/MIC), and the ratio of the area under the 24-h concentration-time curve to MIC (AUC(0-24)/MIC). A single PK/PD index may correlate well with an entire antimicrobial class. For example, the beta-lactams correlate well with the fT>(MIC). However, other classes may be more complex and a single index cannot be generalised to the class, e. g. the macrolides. The rationale behind which PK/PD index best correlates with efficacy depends on several factors, including the mechanism of action, the microbial kill kinetics, the degree of protein binding and the degree of tissue distribution. Studies have traditionally emphasised the first two factors, whilst the significance of protein binding and tissue distribution is increasingly appreciated. In fact, the latter two factors may partially elucidate why the magnitude of reported target indices are not always as expected. For example, tigecycline and telithromycin are clinically efficacious with average serum concentrations below their MICs over a 24-h period. Therefore, to understand more fully the PK/PD relationship of antibiotics and to better predict the clinical efficacy of antibiotic dosing regimens, assessment of free drug concentrations at the site of action is warranted. (C) 2010 Elsevier B. V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:431 / 438
页数:8
相关论文
共 115 条
[1]   VANCOMYCIN SERUM-PROTEIN BINDING DETERMINATION BY ULTRAFILTRATION [J].
ACKERMAN, BH ;
TAYLOR, EH ;
OLSEN, KM ;
ABDELMALAK, W ;
PAPPAS, AA .
DRUG INTELLIGENCE & CLINICAL PHARMACY, 1988, 22 (04) :300-303
[2]   Pharmacokinetics-pharmacodynamics of antimicrobial therapy: It's not just for mice anymore [J].
Ambrose, Paul G. ;
Bhavnani, Sujata M. ;
Rubino, Christopher M. ;
Louie, Arnold ;
Gumbo, Tawanda ;
Forrest, Alan ;
Drusano, George L. .
CLINICAL INFECTIOUS DISEASES, 2007, 44 (01) :79-86
[3]   Pharmacodynamics of fluoroquinolones against Streptococcus pneumoniae in patients with community-acquired respiratory tract infections [J].
Ambrose, PG ;
Grasela, DM ;
Grasela, TH ;
Passarell, J ;
Mayer, HB ;
Pierce, PF .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (10) :2793-2797
[4]  
Amsden GW, 2001, INT J ANTIMICROB AG, V18, pS11, DOI 10.1016/S0924-8579(01)00410-1
[5]   Application of pharmacokinetics and pharmacodynamics to antimicrobial therapy of respiratory tract infections [J].
Andes, D ;
Anon, J ;
Jacobs, MR ;
Craig, WA .
CLINICS IN LABORATORY MEDICINE, 2004, 24 (02) :477-+
[6]   In vivo pharmacodynamics of a new oxazolidinone (linezolid) [J].
Andes, D ;
van Ogtrop, ML ;
Peng, J ;
Craig, WA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (11) :3484-3489
[7]   In vivo pharmacodynamic activity of the glycopeptide dalbavancin [J].
Andes, David ;
Craig, William A. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2007, 51 (05) :1633-1642
[8]  
[Anonymous], 27 INT C ANT AG CHEM
[9]  
*ASTRAZENECA, 2007, MERR I V PRESCR INF
[10]   COMPARISON OF GENTAMICIN DOSING REGIMENS USING AN INVITRO MODEL [J].
BEGG, EJ ;
PEDDIE, BA ;
CHAMBERS, ST ;
BOSWELL, DR .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1992, 29 (04) :427-433